Veterinarians should understand what it means to use conditionally approved drugs, with a focus on conditional approval of companion animal oncology drugs

被引:0
|
作者
Loss, Christopher M. [1 ]
机构
[1] US FDA, Off New Anim Drug Evaluat, Div Compan Anim Drugs, Ctr Vet Med, Rockville, MD 20857 USA
关键词
PACLITAXEL;
D O I
10.2460/javma.22.05.0205
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
The purpose of this article is to provide veterinarians with an understanding of what it means to use a conditionally approved drug. This article summarizes information that has been used to satisfy the reasonable expectation of effectiveness (RXE) standard for conditionally approved companion animal oncology drugs and compares that standard to the substantial evidence of effectiveness (SEE) standard. For conditional approval, the drug company must establish a RXE but need not demonstrate SEE. For a full approval (ie, New Animal Drug Application), the drug company must demonstrate SEE. Information to support a RXE for conditional approval of companion animal oncology drugs has included open-label pilot studies, retrospective analysis of medical records, use of a related formulation, and clinical field studies not meeting their primary effectiveness variable. Oncology drugs are highlighted in this article as they have made up many of the conditionally approved drugs to date. Veterinarians should understand that a conditionally approved drug does not have the same assurance of effectiveness as a drug receiving full approval. However, whether conditionally or fully approved, the drug has been demonstrated to be safe for the intended use. This report did not undergo scientific peer review.
引用
收藏
页码:1562 / 1565
页数:4
相关论文
共 3 条
  • [1] Descriptive epidemiological study of the use of antimicrobial drugs by companion animal veterinarians in New Zealand
    Pleydell, E. J.
    Souphavanh, K.
    Hill, K. E.
    French, N. P.
    Prattley, D. J.
    [J]. NEW ZEALAND VETERINARY JOURNAL, 2012, 60 (02) : 115 - 122
  • [2] Co-Development of Oncology Drugs and Companion Diagnostics: Analyses of Approval Lags and Drug Development Periods in Recently Approved Cases in Japan
    Akari Tanaka
    Hirofumi Suzuki
    Satoshi Toyoshima
    Naomi Nagai
    [J]. Therapeutic Innovation & Regulatory Science, 2022, 56 : 85 - 95
  • [3] Co-Development of Oncology Drugs and Companion Diagnostics: Analyses of Approval Lags and Drug Development Periods in Recently Approved Cases in Japan
    Tanaka, Akari
    Suzuki, Hirofumi
    Toyoshima, Satoshi
    Nagai, Naomi
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2021, 56 (1) : 85 - 95